H.C. Wainwright lowered the firm’s price target on InflaRx to $8 from $9 and keeps a Buy rating on the shares, citing lower revenue expectations based on its probability-adjusted revenue forecasts for Gohibic. The firm is lowering its Q4 Gohibic sales estimate to $1.3M from $4.0M and its 2024 estimate to $15.1M from $22.8M as it believes that while the company’s newly launched Commitment Program may help sales efforts, it could be more difficult than the firm had initially thought for the company to penetrate the COVID-19 hospital market.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IFRX:
- InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients
- InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904
- InflaRx announces ‘positive’ topline results from MAD Phase I study of INF904
